RQ Bio
2 known investors
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease. It focuses on immunocompromised populations such as newborns, the elderly, and patients with weakened immunity who may not respond well to seasonal vaccines.
BiotechHealthtech